Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorthalidone + losartan is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of high blood pressure (hypertension). Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing blood volume. Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the angiotensin II type 1 receptor, leading to vasodilation and reduced aldosterone-mediated sodium retention. Together, these agents lower blood pressure more effectively than either alone, reduce cardiovascular risk (including stroke), and help protect kidney function in patients with diabetes or impaired renal function[1][3][5]. The combination is available as oral tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorthalidone + losartan.